NASDAQ · CYDY
Healthcare · Biotechnology
$0.21
Up+$0.00 (+0.73%)
Updated Sep 24, 2026, 2:43 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYDY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CYDY.
CYDY research
Company profile and research snapshot.
CYTODYN INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2020 | HC Wainwright & Co. | Neutral | — |
| Apr 28, 2020 | HC Wainwright & Co. | Buy | — |
| Apr 3, 2020 | H.C. Wainwright | Buy | — |
| Dec 19, 2019 | H.C. Wainwright | Buy | — |
| Sep 16, 2019 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 19, 2026
CytoDyn (OTCMKTS:CYDY) Chief Financial Officer Robert E. Hoffman outlined the company’s clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors. Speaking at the Life
Yahoo · Sep 18, 2026
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 17th Life Sciences Virtual Investor Forum are available for on-demand viewing. The event featured live presentations from executives representing innovative clinical-stage and commercial companies across the life sciences sector. REGIS
Yahoo · Sep 15, 2026
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Fo
Yahoo · Sep 14, 2026
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Forum taking place on September 17, 2026. REGISTER HERE Individual investors, institutional investors, advisors, and analysts are invited to attend. It is rec
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYDY.
